BPC-157 for Wegener's granulomatosis: what TikTok gets wrong

What did @drautoimmune actually say?

The creator claims that sinus and upper respiratory infections are "the number one trigger" for granulomatosis with polyangiitis (GPA, formerly Wegener's), and that these infections combine with antibodies to form what he calls a "super antigen" that causes the immune system to "freak out." He also implies that antibiotics are not the right fix for the sinus component, and that downstream triggers need to be addressed separately.

He's responding to a viewer question, speaking quickly, and the terminology gets a bit loose. "Super antigen" and "super immune complex" are not the same thing, and he appears to conflate the two. That matters, as we'll get into.

Does the science back this up?

Partially, yes. The sinus-infection-to-GPA connection is real and reasonably well-supported. Staphylococcus aureus nasal carriage has been linked to GPA relapse in multiple studies. Popa et al. (2007, Arthritis & Rheumatism) showed that trimethoprim-sulfamethoxazole reduced relapse rates in GPA patients, specifically by targeting nasal S. aureus, which is a notable finding. The leading hypothesis is that S. aureus proteins act as superantigens, triggering polyclonal T-cell activation that drives ANCA production.

So the broad direction is correct: chronic upper respiratory infection, particularly bacterial, plays a role in GPA pathogenesis and relapse. However, calling it "the number one trigger" overstates certainty. The full etiology of GPA remains incompletely understood, and genetic, environmental, and immune dysregulation factors all contribute. Lyons et al. (2012, Arthritis & Rheumatism) found geographic and occupational exposures also correlate with GPA incidence.

What did they get wrong (or right)?

The "super antigen" terminology is used loosely here. A superantigen is a specific type of bacterial or viral protein that bypasses normal antigen presentation and activates large numbers of T-cells nonspecifically. An immune complex is an antibody-antigen aggregate. These are distinct mechanisms, and conflating them in a clinical explanation is sloppy, even if both concepts are relevant to GPA pathophysiology.

The claim that the infection "combines with antibodies" to form a super immune complex is not a recognized description of GPA pathogenesis. ANCA-associated vasculitis like GPA is driven by ANCA antibodies (specifically PR3-ANCA) that activate neutrophils, causing vessel wall inflammation. That's different from classical immune complex deposition, which is more characteristic of lupus nephritis or IgA vasculitis. GPA is actually notable for being a pauci-immune vasculitis, meaning there is relatively little immune complex deposition on biopsy. Getting this wrong on a platform with 72K views is a meaningful clinical error.

Credit where it's due: the point that GPA can affect kidneys, heart, and other organs is accurate. And the idea that treating the upstream infection matters is supported by evidence.

What should you actually know?

GPA is a serious, potentially life-threatening condition. It requires diagnosis by a rheumatologist, typically confirmed with ANCA serology and biopsy. Standard of care for active GPA involves immunosuppressive therapy, including rituximab or cyclophosphamide plus glucocorticoids, per the 2021 ACR/EULAR guidelines. Trimethoprim-sulfamethoxazole is used as adjunct therapy for remission maintenance and S. aureus suppression, not as primary treatment.

The implied suggestion that antibiotics are not useful here is misleading in context. While antibiotics alone cannot treat active GPA, the evidence specifically supports antibiotic prophylaxis targeting S. aureus as part of a comprehensive management plan. Telling patients to skip antibiotics without that nuance could be harmful.

If you have GPA or suspect you might, you need a rheumatologist, not a TikTok video. This condition can progress to renal failure and respiratory failure without appropriate treatment. Functional medicine approaches may complement care but are not a substitute for disease-modifying therapy.

What's the bottom line on peptides and GPA?

The video is tagged under peptide therapy on this platform, but the creator does not mention any specific peptide in the transcript. No evidence currently supports the use of peptides like BPC-157 or TB-500 for GPA management. These compounds have shown anti-inflammatory and gut-healing properties in preclinical models, but no human trials exist for ANCA-associated vasculitis. Claims connecting peptide therapy to autoimmune vasculitis treatment would be speculative at best.